MedTrace Logo

Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

NCT03189030 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-10-01

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.

Conditions

  • Colorectal Neoplasms

Interventions

BIOLOGICAL

pLADD

via IV infusion

Sponsors & Collaborators

  • Hanlee P. Ji, MD

    collaborator UNKNOWN

  • Aduro Biotech, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-02
Primary Completion
2019-10-15
Completion
2020-09-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03189030 on ClinicalTrials.gov